Impaired Renal Function Clinical Trial
Official title:
Impact of a Counselling System Coupled With a Computer Prescribing System to Optimize the Use of the Drugs for Old Subjects Having Renal Function Impairment
To evaluate the quality of orders for target drugs in old patients with impaired renal function, hospitalized or living in long stay units, and to improve these practices by means of a counselling system coupled to a computer prescribing system
Context: The incidence of drug side effects increases with patient age, and the frail old
subjects hospitalized in geriatric units are particularly exposed to this risk. Optimizing
drug prescription is an important issue to prevent the side effects. Among the various
possible actions, it is important to pay attention to impaired renal function which requires
careful dose adjustment for drugs eliminated by renal way.
Objective: To evaluate the quality of orders for target drugs in old patients with impaired
renal function, hospitalized or living in long stay units, and to improve these practices by
means of counselling system coupled to a computer prescribing system. The computer
prescribing system allow (a) to detect in real-time the order of drugs contraindicated in
case of renal failure or prescribed in excessive amount taking into account the creatinine
clearance (ClCr), and (b) to counsel the physician in these situations.
Participants: A coordinating centre (team of geriatrics 1, hospital Charles Foix,
Ivry-sur-Seine, France), and 12 hospital investigator centres (hospital services of
geriatrics working already in network, including the co-ordinating centre), and the
department of Biostatistics (hospital Pitié-Salpétrière, Paris)
Type of study: Intervention study, cluster randomised, open, parallel.
General design: The investigator centres will be equipped with the electronic prescribing
system (EPS) developed for the project. For each patient, the software requires the seizure
of weight and plasma creatinine and calculates ClCr using Cockcroft formula, from which the
result is accessible to the physician. After a phase of training of the EPS, the quality of
the orders given to old subjects having renal failure (defined by ClCr<60 ml/mn) will be
studied for 3 months under natural conditions of prescribing, without use of the counselling
system (sequence A). After this phase, the counselling system will be activated for 6 months
(sequence B) in 6 investigatory centres chosen by a cluster randomisation process. The
centres were paired by the numbers of orders during the sequence A. For each pair, the
centres were allocated to either intervention or control group by a randomisation table.
Reference frame to evaluate the quality of target drug orders:This reference frame aims to
analyze the respect of the mentions of the "summaries of characteristics of products" (or
RCP) relative to the impaired renal function. Drug RCP is a health authorities-approved
document which describes in detail the information for prescribing. It corresponds in the US
to the FDA-approved Full prescribing information. Using an automated analysis of the RCP, we
will identify target drugs, defined as drugs which are contraindicated in case of renal
failure or are cited in precautions for use for patient with impaired renal function. For
each speciality thus identified, the possible thresholds of ClCr implied to define the
counter-indication or the adjustment of dose will be sought by reading and analyzes CCP. An
order line will be regarded as inappropriate if the drug is contraindicated in renal failure
or if the dose prescribed exceeds that indicated in RCP for the level of patient's ClCr.
Counselling system: This system will operate in patients with ClCr <60 ml/mn. It will
comprise three functionalities: (a) detection of orders of a drug contraindicated in case of
renal failure and production of an alert message; (b) detection of excessive dose taking
into account patient's ClCr and production of an alert message; (c) counsel to monitor
plasma concentration of drugs having a renal elimination in the event of impaired renal
function. This system will be very largely based on the data obtained to work out the
reference frame.
Intervention: The investigator centres will be allocated to the group Intervention (6
centres) or Controls, without intervention (6 centres). The intervention applied for 6
months (sequence B), consists in activating the counselling system. An alert message
indicates to the physician, according to the case, that the drug is contraindicated in the
event of impaired renal function or that dose must be adjusted, by indicating the amounts
recommended adjusted to ClCr when it are mentioned in the CCP. The physician keeps the final
choice of his order and the prescribed dose. If the final choice differs from the counsel of
the system of council the reason for the maintenance of the regulation is asked.
Data collection: Information concerning the investigator centres and the patients (type of
stay, age, sex, weight, score of dependence of Activities off daily living room (ADL), index
of co morbidity, plasma creatinine); occurred of adverse drug reactions and their
description; lines of orders. All the data necessary for the study will be recorded through
the EPS and seizures by the physician will be transmitted to the co-ordinating centre after
encoding via Internet network.
Statistical analysis: The analysis will relate on the patients having ClCr lower than 60
mL/mn during the duration of the study and to the orders which are made to them. The
characteristics of the patients of each group (Control/Intervention) and the proportion of
target drugs will be studied and compared during the sequence A, then during the sequence B.
We will compare the reductions in the proportions of inappropriate target drug orders
between the sequences B and A between the Intervention group and Control (principal
judgement criterion). In addition will be required in the Intervention units the existence
during the 6 months of use of a possible effect of training of the physicians (progressive
transfer of the expertise to the physician) which could result in a time-related reduction
in the number of counsels generated by physician. Lastly, the adverse drug reactions which
have occurred during the study period will be collected to analyze their nature, their
incidence and their possible bonds with impaired renal function in order to guide future
studies on this set of themes.
Expected results: If such a system proves to be effective to optimize prescribing of the
drugs among in-patients having impaired renal function and if it is well accepted by the
physicians, diffusion could be considered in centres of geriatrics. In the same way, similar
studies in hospital medical wards with no geriatricians in their staff or also in family
medicine settings could be considered. The algorithms will be made available for the
developers which would wish to integrate it into other applications of regulations.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04252430 -
RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects
|
Phase 1 | |
Completed |
NCT01716455 -
Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
|
Phase 1 | |
Completed |
NCT02431481 -
Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011
|
Phase 1 | |
Completed |
NCT02087566 -
Linezolid Pharmacokinetics In Patients With Impaired Renal Function (PPT6)
|
N/A | |
Completed |
NCT04179630 -
Study of Aldafermin (NGM282) in Participants With Impaired Renal Function
|
Phase 1 | |
Completed |
NCT00779922 -
Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
|
Phase 2 | |
Completed |
NCT01507350 -
Effects of Obesity Surgery on Renal Function
|
||
Active, not recruiting |
NCT01760031 -
Longterm Follow-up After Remote Ischemic Preconditioning for Prevention of Contrast-induced Nephropathy
|
N/A | |
Completed |
NCT03776539 -
A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
|
Phase 1 | |
Completed |
NCT01035320 -
Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment
|
Phase 4 | |
Completed |
NCT00604357 -
CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment
|
Phase 3 | |
Completed |
NCT02965040 -
A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function
|
Phase 1 | |
Completed |
NCT00981045 -
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
|
Phase 3 | |
Completed |
NCT02467478 -
Linagliptin's Effect on CD34+ Stem Cells
|
Phase 4 | |
Recruiting |
NCT04620590 -
An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function
|
Phase 4 |